PL4205732T3 - Kompozycja kannabinoidowa i jej zastosowanie w przygotowaniu leku do leczenia chorób neurodegeneracyjnych takich jak choroba parkinsona i choroba alzheimera - Google Patents
Kompozycja kannabinoidowa i jej zastosowanie w przygotowaniu leku do leczenia chorób neurodegeneracyjnych takich jak choroba parkinsona i choroba alzheimeraInfo
- Publication number
- PL4205732T3 PL4205732T3 PL21953377.5T PL21953377T PL4205732T3 PL 4205732 T3 PL4205732 T3 PL 4205732T3 PL 21953377 T PL21953377 T PL 21953377T PL 4205732 T3 PL4205732 T3 PL 4205732T3
- Authority
- PL
- Poland
- Prior art keywords
- disease
- parkinson
- alzheimer
- medicine
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110916566.9A CN113368086B (zh) | 2021-08-11 | 2021-08-11 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
| PCT/CN2021/133379 WO2023015772A1 (zh) | 2021-08-11 | 2021-11-26 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4205732T3 true PL4205732T3 (pl) | 2026-04-07 |
Family
ID=77576733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21953377.5T PL4205732T3 (pl) | 2021-08-11 | 2021-11-26 | Kompozycja kannabinoidowa i jej zastosowanie w przygotowaniu leku do leczenia chorób neurodegeneracyjnych takich jak choroba parkinsona i choroba alzheimera |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11497719B1 (pl) |
| EP (1) | EP4205732B1 (pl) |
| JP (1) | JP7220818B1 (pl) |
| KR (1) | KR102623984B1 (pl) |
| CN (1) | CN113368086B (pl) |
| AU (1) | AU2021459955B2 (pl) |
| CA (1) | CA3192406C (pl) |
| DK (1) | DK4205732T3 (pl) |
| ES (1) | ES3062607T3 (pl) |
| FI (1) | FI4205732T3 (pl) |
| HR (1) | HRP20260264T1 (pl) |
| IL (1) | IL302085A (pl) |
| LT (1) | LT4205732T (pl) |
| MA (1) | MA65559B1 (pl) |
| MD (1) | MD20250033A2 (pl) |
| MX (1) | MX2024001818A (pl) |
| NZ (1) | NZ807398A (pl) |
| PL (1) | PL4205732T3 (pl) |
| PT (1) | PT4205732T (pl) |
| RS (1) | RS67760B1 (pl) |
| SI (1) | SI4205732T1 (pl) |
| SM (1) | SMT202600078T1 (pl) |
| WO (1) | WO2023015772A1 (pl) |
| ZA (1) | ZA202400378B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368086B (zh) * | 2021-08-11 | 2021-12-03 | 龙麻(上海)医药研发有限责任公司 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
| KR20240036952A (ko) * | 2022-09-14 | 2024-03-21 | 주식회사 네오켄바이오 | 칸나비노이드를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 및 이의 용도 |
| US20240350592A1 (en) * | 2023-04-12 | 2024-10-24 | Xygenyx Inc. | Composition and methods of treatment using synergistically-enhanced supplementation |
| WO2026018132A1 (en) * | 2024-07-16 | 2026-01-22 | Buzzelet Development And Technologies Ltd. | Cannabinoid-containing compositions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| ES2359168T3 (es) * | 2007-10-02 | 2011-05-19 | Vivacell Biotechnology España S.L. | Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias. |
| GB2527590A (en) * | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| AU2017319702B2 (en) * | 2016-09-02 | 2024-11-14 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| CN109963595B (zh) * | 2016-10-11 | 2023-02-03 | Gbs全球生物制药公司 | 用于治疗神经退行性疾病的含有大麻素的复合混合物 |
| GB2559774B (en) * | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| EP3589129A4 (en) * | 2017-03-01 | 2020-11-25 | Canopy Growth Corporation | TARGETEDLY SELECTED COMPOSITIONS CONTAINING PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENES |
| CN107095302A (zh) * | 2017-05-09 | 2017-08-29 | 何宗迅 | 大麻素类混合物及其在食品工业中的应用 |
| US12324789B2 (en) * | 2017-08-28 | 2025-06-10 | Apirx Pharmaceutical Usa, Llc | Method to treat psoriasis |
| US11484510B2 (en) * | 2017-08-28 | 2022-11-01 | Apirx Pharmaceutical Usa, Llc | Method to treat vitiligo |
| US11622956B1 (en) * | 2019-06-26 | 2023-04-11 | RCR BioPharma | Compound and method for treating diseases and disorders |
| CN113116869B (zh) * | 2019-12-31 | 2022-08-23 | 汉义生物科技（北京）有限公司 | 一种预防和/或治疗抑郁的组合物 |
| WO2022043961A1 (en) * | 2020-08-31 | 2022-03-03 | Nelson Mandela University | Cannabinoid combinations and their use in the treatment of cancer |
| GB202101732D0 (en) * | 2021-02-08 | 2021-03-24 | Tts Pharma Ltd | A cannabinoid mixture |
| CN113368086B (zh) * | 2021-08-11 | 2021-12-03 | 龙麻(上海)医药研发有限责任公司 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
| EP4408404A4 (en) * | 2021-09-28 | 2025-10-29 | Gbs Global Biopharma Inc | Formulations containing cannabinoids for Parkinsonian movement disorders |
-
2021
- 2021-08-11 CN CN202110916566.9A patent/CN113368086B/zh active Active
- 2021-11-23 MA MA65559A patent/MA65559B1/fr unknown
- 2021-11-26 PL PL21953377.5T patent/PL4205732T3/pl unknown
- 2021-11-26 ES ES21953377T patent/ES3062607T3/es active Active
- 2021-11-26 RS RS20260204A patent/RS67760B1/sr unknown
- 2021-11-26 FI FIEP21953377.5T patent/FI4205732T3/fi active
- 2021-11-26 PT PT219533775T patent/PT4205732T/pt unknown
- 2021-11-26 MD MDA20250033A patent/MD20250033A2/ro unknown
- 2021-11-26 MX MX2024001818A patent/MX2024001818A/es unknown
- 2021-11-26 SM SM20260078T patent/SMT202600078T1/it unknown
- 2021-11-26 AU AU2021459955A patent/AU2021459955B2/en active Active
- 2021-11-26 WO PCT/CN2021/133379 patent/WO2023015772A1/zh not_active Ceased
- 2021-11-26 EP EP21953377.5A patent/EP4205732B1/en active Active
- 2021-11-26 KR KR1020237011823A patent/KR102623984B1/ko active Active
- 2021-11-26 NZ NZ807398A patent/NZ807398A/en unknown
- 2021-11-26 HR HRP20260264TT patent/HRP20260264T1/hr unknown
- 2021-11-26 IL IL302085A patent/IL302085A/en unknown
- 2021-11-26 LT LTEPPCT/CN2021/133379T patent/LT4205732T/lt unknown
- 2021-11-26 DK DK21953377.5T patent/DK4205732T3/da active
- 2021-11-26 SI SI202130403T patent/SI4205732T1/sl unknown
- 2021-11-26 CA CA3192406A patent/CA3192406C/en active Active
-
2022
- 2022-01-27 US US17/586,304 patent/US11497719B1/en active Active
- 2022-02-02 JP JP2022015041A patent/JP7220818B1/ja active Active
-
2024
- 2024-01-10 ZA ZA2024/00378A patent/ZA202400378B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113368086B (zh) | 2021-12-03 |
| MD20250033A2 (ro) | 2025-08-31 |
| IL302085A (en) | 2023-06-01 |
| CN113368086A (zh) | 2021-09-10 |
| ZA202400378B (en) | 2024-03-27 |
| KR20230123010A (ko) | 2023-08-22 |
| PT4205732T (pt) | 2026-02-24 |
| MA65559A1 (fr) | 2025-02-28 |
| NZ807398A (en) | 2024-05-31 |
| RS67760B1 (sr) | 2026-03-31 |
| LT4205732T (lt) | 2026-03-25 |
| HRP20260264T1 (hr) | 2026-04-10 |
| FI4205732T3 (fi) | 2026-03-12 |
| EP4205732A1 (en) | 2023-07-05 |
| WO2023015772A1 (zh) | 2023-02-16 |
| MA65559B1 (fr) | 2025-12-31 |
| CA3192406C (en) | 2024-04-09 |
| US11497719B1 (en) | 2022-11-15 |
| JP7220818B1 (ja) | 2023-02-10 |
| MX2024001818A (es) | 2024-03-06 |
| SI4205732T1 (sl) | 2026-04-30 |
| AU2021459955A1 (en) | 2023-04-13 |
| KR102623984B1 (ko) | 2024-01-11 |
| DK4205732T3 (da) | 2026-02-23 |
| JP2023026291A (ja) | 2023-02-24 |
| EP4205732B1 (en) | 2026-01-28 |
| AU2021459955B2 (en) | 2023-09-14 |
| ES3062607T3 (en) | 2026-04-13 |
| SMT202600078T1 (it) | 2026-03-09 |
| CA3192406A1 (en) | 2023-02-16 |
| EP4205732A4 (en) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4205732T3 (pl) | Kompozycja kannabinoidowa i jej zastosowanie w przygotowaniu leku do leczenia chorób neurodegeneracyjnych takich jak choroba parkinsona i choroba alzheimera | |
| MA50800A (fr) | Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson | |
| EP4153210A4 (en) | MULTIPLE EPITOPE VACCINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| MX375424B (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl | |
| EP3405215A4 (en) | METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| IL288894A (en) | Methods for the assessment and treatment of Alzheimer's disease and their applications | |
| IL309208A (en) | Neuroactive steroid for the treatment of alzheimer's disease | |
| EP4259188A4 (en) | PEPTIDE THERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | |
| UA101393C2 (ru) | КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| IL282562A (en) | Composition and use for the treatment of parkinson's disease and related disorders | |
| MX2021000515A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| CY1110401T1 (el) | Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων | |
| EP4370131A4 (en) | METHODS FOR TREATING ALZHEIMER'S DISEASE | |
| DK1751097T3 (da) | Substituerede N-aryl-benzamider og relaterede sammensætninger til behandling af amyloid-sygdomme og synukleinopatier | |
| EP3628008A4 (en) | COMPOSITION AND METHOD OF TREATMENT OF ALZHEIMER'S MORBUS | |
| EP4087654A4 (en) | TREATMENT OF ALZHEIMER'S DISEASE | |
| EP3727416A4 (en) | PURE SKIN SUPPLEMENT AND MEDICAL COMPOSITION FOR ACNE | |
| EP4228628A4 (en) | METALLOENZYME INHIBITORS FOR THE TREATMENT OF CANCER, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS AND OTHER DISORDERS | |
| EP4047007C0 (en) | PEPTIDE AND ITS USE IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF INFLAMMATORY DISEASES AND PAIN | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| EP4236988A4 (en) | INTRANASAL IMMUNOTHERAPY FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL271795A (en) | A screening platform to identify drugs or medical substances for the treatment of Alzheimer's disease | |
| HK40084051A (en) | Treatment of alzheimer's disease |